Animas

History

2017: Closing of business on release of insulin pumps

On October 5, 2017 Johnson & Johnson announced closing of business on release of insulin pumps which was developed by Animas subsidiary company. The decision was made against the background of gain of the competition and after failure attempts to find buyers of these assets, Reuters reports.

Animas  stops production and sale of insulin pumps of Animas, Vibe and OneTouch Ping. By the beginning of October, 2017 about 90 thousand used these devices human. It is recommended to all of them to pass to the equipment of Medtronic company.

Insulin pumps of Animas

As the representative of Johnson & Johnson Bridget Doherty specified to news agency, sales of pumps of Animas Vibe and OneTouch Ping will be stopped only in the USA and Canada so far.

The analyst of William Blair Margaret Kaczor considers unsurprising leaving of Animas from the market of insulin pumps. The company abstained from large investments into the products and from active expansion of a patent portfolio for the last year, the expert noted.

In January, 2017 Johnson & Johnson began to study strategic options on diabetic division (including its sale) to which, in addition to Animas, products of the Calibra Medical and LifeScan brands belong. In the second quarter 2017 revenue of division made $421 million that is 10.6% less than an indicator of year prescription.^[1]

2004-2006

Animas went public in May, 2004, its shares began to be traded under a ticker of PUMP.

At the end of December, 2005 Johnson & Johnson announced purchase of Animas for $518 million. The transaction was closed on February 18 the 2006th. After this Animas became a part of diabetic division of Johnson & Johnson.

Notes